Gavilimomab

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]

Gavilimomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetCD147
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

It was originally developed by Abgenix,[1] which was later acquired by Amgen.

References
  1. "Gavilimomab". Adis Insight. Springer Nature Switzerland AG.
  2. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, et al. (March 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease". Blood. 109 (6): 2657–62. doi:10.1182/blood-2006-08-013995. PMID 17110457.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.